QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.006122v1 34/2/261    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Westley, I. S. Articles by Sallustio, B. C. Search for Related Content PubMed PubMed Citation Articles by Westley, I. S. Articles by Sallustio, B. C.

ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE

Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia (I.S.W., R.G.M., B.C.S.); Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, South Australia, Australia (R.G.M., B.C.S.); and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia (I.S.W., L.R.B., A.M.E.)

Mycophenolic acid (MPA) is part of the immunosuppressant therapy for transplant recipients. This study examines the role of the canalicular transporter, Mrp2, and the effect of cyclosporin A (CsA), on the biliary secretion of the ether (MPAGe) and acyl (MPAGa) glucuronides of MPA. Isolated livers from Wistar rats (n = 6), or Wistar TR^– rats (n = 6) were perfused with MPA (5 mg/l). A third group of Wistar rats (n = 6) was perfused with MPA and CsA (250 µg/l). There was no difference in the half-life, hepatic extraction ratio (E_H), clearance or partial clearance of MPA to MPAGe, but there was a difference in partial clearance to MPAGa between control and CsA groups (0.9 ± 0.4 versus 0.5 ± 0.1 ml/min). TR^– rats had a lower E_H (0.59 ± 0.30 versus 0.95 ± 0.30), a lower clearance (18 ± 8 versus 29 ± 7 ml/min), and a longer half-life (19.5 ± 10.3 versus 10.1 ± 2.4 min) than controls. Compared to controls, MPAGe and MPAGa biliary excretion was reduced by 99% and 71.8%, respectively, in TR^– rats, and 17.5% and 53.8%, respectively, in the MPA-CsA group. The biliary excretion of MPAGe is mediated by Mrp2, whereas that of MPAGa seems to depend on both Mrp2 and another unidentified canalicular transporter. Although CsA can inhibit Mrp2, our data suggest that it may also inhibit the hepatic glucuronidation of MPA in Wistar rats.

This article has been cited by other articles:

				I. Neumann, H. Fuhrmann, I-F. Fang, A. Jaeger, P. Bayer, and J. Kovarik Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3514 - 3520. [Abstract] [Full Text] [PDF]

				I. S. Westley, R. G. Morris, A. M. Evans, and B. C. Sallustio Glucuronidation of Mycophenolic Acid by Wistar and Mrp2-Deficient TR- Rat Liver Microsomes Drug Metab. Dispos., January 1, 2008; 36(1): 46 - 50. [Abstract] [Full Text] [PDF]

				N. A. Wolff, B. C. Burckhardt, G. Burckhardt, M. Oellerich, and V. W. Armstrong Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2497 - 2503. [Abstract] [Full Text] [PDF]

				S. T. Stern, M. N. Tallman, K. K. Miles, J. K. Ritter, R. E. Dupuis, and P. C. Smith Gender-Related Differences in Mycophenolate Mofetil-Induced Gastrointestinal Toxicity in Rats Drug Metab. Dispos., March 1, 2007; 35(3): 449 - 454. [Abstract] [Full Text] [PDF]

				H. Jeong and B. Kaplan Therapeutic Monitoring of Mycophenolate Mofetil Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 184 - 191. [Full Text] [PDF]